【摘要】 目的应用沙利度胺进行小细胞肺癌(SCLC)维持治疗,观察其对患者生存质量的影响。方法将完成规定周期化疗28例SCLC随机分为治疗组和对照组,每组各14例。治疗组应用沙利度胺100 mg/d,连续睡前顿服至少2个疗程(21 d为1个疗程);对照组定期复查随访。结果治疗组和对照组的功能状态Karnofsky评分改善率分别为71.43%和28.57%,两组比较差异无统计学意义(P=0.075);体重增加率为64.29%和28.57%,两组比较差异无统计学意义(P=0.058);两组治疗前后、治疗组治疗前后、对照组治疗前后生活质量(QOL)评分比较,差异均无统计学意义(P>0.05)。治疗组6例出现轻度不良反应,两组均未见严重药物不良反应。结论沙利度胺用于SCLC的维持治疗是安全的,对患者的生存质量无明显影响。更多还原

【Abstract】 Objective To observe the effects of Thalidomide on the life quality of the SCLC patients as a maintenance treatment.Methods A total of 28 SCLC patients undergoing complete circular chemotherapy were randomly divided into treatment group and control group(n=14 in each).The treatment group was treated with Thalidomide(100 mg/d,in one single dose) before sleep for 2 courses of treatment(21 days as a course);the control group did not receive any intervention.Regular observations and follow-up were performed in both groups. Results Karnofsky scores in the treatment group and control group were 71.43% and 28.57% respectively,and the differences between the two groups were not significant(P=0.075).The weight increasing rates were 64.29% and 28.57%,and the difference was not significant(P=0.058);there was no significant difference in Quality Of Life(QOL) in both groups before and after treatment,and no significant difference between the two groups(P>0.05).6 patients had slight adverse reaction,but no serious adverse events occurred in both groups. Conclusion Thalidomide as a maintenance treatment is safe in patients with SCLC,without affecting the life quality.更多还原